Law.com Subscribers SAVE 30%

Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.

Search


Counterfeit Drugs: FDA Suggests New Counter Measures
October 16, 2003
<b><i>No 'Magic Bullet,' Says Task Force</i></b> The FDA's Counterfeit Drug Task Force issued its interim report on October 2. It contains potential options for a multi-pronged approach to combat counterfeit drugs. In recent years, the FDA has seen an increase in the number and sophistication of efforts to introduce counterfeit drugs. The FDA noted at the time the report was issued that the problem of counterfeit drugs is being treated separately from the problem of unapproved and potentially unsafe drugs that are being imported via the Internet and other unregulated international channels. Under current law, those drugs are purchased outside of U.S. and foreign consumer protection systems, so they are "buyer beware" products that have traveled outside of the regulatory protections of the legal U.S. drug distribution system.
<i>Daubert </i>Tool Lets Lawyers Track History of Experts
October 16, 2003
Expert testimony can be the linchpin that makes or breaks a case. But lawyers have had a tougher time getting that testimony admitted since 1993, when the U.S. Supreme Court decided in <i>Daubert v. Merrell Dow Pharmaceuticals</i> that scientific testimony must be not only relevant, but reliable. In 1999's <i>Kumho Tire v. Carmichael</i>, the Court extended that rule to all experts. This means that a lawyer preparing to qualify or challenge an expert at trial must answer a number of questions. What is the state of the case law under <i>Daubert</i>? How has the particular court or judge applied the rule? How have courts ruled on this type of expertise? Has this expert ever come before a judge?
Over-the-Border Drug Debate Heats to Boiling
October 16, 2003
<b><i>The State of the Re-Importation Debate</i></b> When Gov. Rod R. Blagojevich of Illinois announced in mid-September that his state was considering buying drugs from Canada for its employees and citizens, the debate over cross-border drug purchases via the Internet and by other means, got even hotter than it was before. The pharmaceutical industry is fighting a battle similar in scope to the music industry's Internet copyright infringement war, but because no suits have been brought against 80-year-old diabetics buying insulin from pharmacies in Montreal, national debate on the issue of the purchase of foreign drugs has gotten less press of late than the debate over music piracy.
Case Briefing
October 16, 2003
The latest rulings of importance to your practice.
News from the FDA
October 16, 2003
The latest information for use in your practice, including rulings, draft guidances, seminars, and more.
Quiz of the Month
October 16, 2003
Test your knowledge of the law!

MOST POPULAR STORIES

  • The Anti-Assignment Override Provisions
    UCC Sections 9406(d) and 9408(a) are one of the most powerful, yet least understood, sections of the Uniform Commercial Code. On their face, they appear to override anti-assignment provisions in agreements that would limit the grant of a security interest. But do these sections really work?
    Read More ›
  • Chambers & Partners: What's New After Sale
    On Nov. 10, 2023, Abry Partners, a leading North American middle market private equity firm, announced that it had acquired Chambers & Partners for $449 million from Inflexion, the UK private equity firm that purchased Chambers in 2018. What will this mean?
    Read More ›
  • The Article 8 Opt In
    The Article 8 opt-in election adds an additional layer of complexity to the already labyrinthine rules governing perfection of security interests under the UCC. A lender that is unaware of the nuances created by the opt in (may find its security interest vulnerable to being primed by another party that has taken steps to perfect in a superior manner under the circumstances.
    Read More ›